This is a non-core endpoint: only basic statistics are computed.

See these related core endpoints for full statistics:

CD2_INSITU_MELANOMA_EXALLC

Melanoma in situ of eyelid, including canthus

CD2_INSITU_MELANOMA_EYELID

melanoma: A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.

Suggest a new description

Endpoint definition

↥

Endpoint definition steps	FinnGen
Phenotype data	520210
1. Apply sex-specific rule None	520210
2. Check conditions None	520210
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — D03.1& Cause of death: ICD-10 — D03.1& 2 out of 7 registries used, show all original rules.	21
4. Check minimum number of events None	21
5. Include endpoints None	21
6. Filter based on genotype QC (FinnGen only)	21

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy: 3
First used in FinnGen datafreeze: DF2
Parent code in ICD-10: D03
Name in latin: Melanoma in situ palpebrae

NAME	CD2_INSITU_MELANOMA_EYELID
CONTROL_EXCLUDE
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	D031
HD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	D031
COD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Melanoma in situ of eyelid, including canthus based on the number of shared cases.

Similar with more cases:

Similar with less cases:

Melanoma in situ of eyelid, including canthus

Case counts by codes

↥

FinnGen case counts by registry codes:

Not enough data for upset plot.

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	21	11	10
Unadjusted period prevalence (%)	0.00	0.00	0.00
Median age at first event (years)	64.56	65.07	64.00

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

No data available

LabWAS

↥

(ID) Name

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(40768804) Tissue Pathology biopsy report

3.37

1.84

3.9

2.2

—

(3013512) EKG study

2.57

1.19

3.7

4.8

—

(40761511) CBC panel - Blood by Automated count

183

+∞

0.84

15.8

15.4

—

(3002256) Pathology report gross observation

2.53

0.83

2.0

1.1

—

(3016771) Amylase [Enzymatic activity/volume] in Serum or Plasma

1.91

0.72

2.5

2.4

54.6

59.2

u/l

—

(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture

0.00

0.64

0.0

1.3

—

(3037467) Urinalysis macro (dipstick) panel - Urine

131

1.92

0.61

5.6

4.9

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

1.72

0.47

3.2

3.9

—

(40758558) Short blood count panel - Blood

1.46

0.38

7.7

8.4

—

(3003694) ABO and Rh group [Type] in Blood

1.46

0.38

1.3

—

(1761868) Lipid panel - Serum or Plasma

1.52

0.36

2.6

3.3

—

(3041096) Erythrocytes [Presence] in Urine by Automated

1.48

0.36

2.1

3.9

—

(36304419) Bacteria [Presence] in Urine

1.44

0.35

3.4

2.7

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

1.47

0.33

2.7

4.6

—

(3011397) Hemoglobin [Presence] in Urine by Test strip

1.29

0.24

2.4

4.2

—

(3015399) Transferrin receptor.soluble [Mass/volume] in Serum or Plasma

1.39

0.23

1.3

2.1

3.4

3.2

mg/l

—

(46235759) Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection

0.00

0.22

0.0

1.2

—

(3015736) pH of Urine

1.23

0.20

2.4

4.2

—

(3044889) 12 lead EKG panel

132

0.79

0.19

4.3

4.4

—

(3013826) Glucose [Moles/volume] in Serum or Plasma

106

1.31

0.19

2.9

5.0

6.3

7.0

mmol/l

0.85

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

1.34

0.16

2.5

1.9

—

(3030467) Casts [#/volume] in Urine by Automated count

0.78

0.10

3.8

2.7

0.0

0.5

e6/l

—

(3044640) Blood type and Crossmatch panel - Blood

1.10

0.10

3.0

2.1

—

(3015171) Extractable nuclear Ab [Units/volume] in Serum

0.00

0.0

1.4

—

(40760888) Immunoglobulin light chains.free panel - Serum

0.00

0.0

10.0

—

(3030366) Cystatin C [Mass/volume] in Serum or Plasma

0.00

0.0

6.4

—

2.5

—

(3017766) Complement C4 [Mass/volume] in Serum or Plasma

0.00

0.0

1.4

—

0.3

—

(3010566) Parathyrin.intact [Moles/volume] in Serum or Plasma

0.00

0.0

4.4

—

(3042111) Morphology [Interpretation] in Bone marrow Narrative

0.00

0.0

1.6

—

(1616796) Gas panel - Central venous blood

0.00

0.0

5.6

—

(3017044) Thyrotropin receptor Ab [Units/volume] in Serum

0.00

0.0

1.0

—

(40765161) Human bocavirus DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.0

—

(36660697) Celiac disease serology panel - Serum

0.00

0.0

2.0

—

(3040853) Adenovirus DNA [Identifier] in Specimen by NAA with probe detection

0.00

0.0

1.0

—

(3050380) Cytology report of Cervical or vaginal smear or scraping Cyto stain

0.00

0.0

1.2

—

(3028271) Lactate [Moles/volume] in Capillary blood

0.00

0.0

1.4

—

1.3

—

(3042194) Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.0

—

(3023368) Bacteria identified in Blood by Culture

1.08

0.00

4.6

4.1

—

(3014007) Fractional oxyhemoglobin in Arterial blood

0.00

0.0

10.9

—

95.0

—

(42870588) Differential panel, method unspecified - Blood

0.98

0.00

5.5

5.0

—

(3035797) Protein.monoclonal band 2 [Mass/volume] in Serum or Plasma by Electrophoresis

0.00

0.0

7.3

—

0.0

—

(3001122) Ferritin [Mass/volume] in Serum or Plasma

1.02

0.00

2.7

77.6

129.1

ug/l

—

(3029187) Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma

0.85

0.00

3.5

3.7

657.3

1265.9

ng/l

—

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

0.92

0.00

3.4

2.9

—

(3029713) Protein.monoclonal band 1 [Mass/volume] in Serum or Plasma by Electrophoresis

0.00

0.0

7.3

—

0.8

—

(3025839) Triglyceride [Moles/volume] in Serum or Plasma

0.97

0.00

1.8

1.6

1.1

1.2

mmol/l

—

(3015322) Alpha 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis

0.00

0.0

7.3

—

3.3

—

(3013290) Carbon dioxide [Partial pressure] in Blood

0.00

0.0

3.1

—

4.7

—

(4094501)

0.00

0.0

1.5

—

(3019250) Coagulation factor VIII activity actual/normal in Platelet poor plasma by Coagulation assay

0.00

0.0

4.0

—

253.0

—

(3000620) Complement C3 [Mass/volume] in Serum or Plasma

0.00

0.0

1.3

—

1.3

—

(3003338) MCHC [Mass/volume]

139

1.02

0.00

19.5

21.7

332.2

331.1

g/l

0.14

139

(3036489) Thrombin time

0.00

0.0

3.8

—

21.1

—

(3033319) Streptococcus pyogenes Ag [Presence] in Throat

0.00

0.0

1.0

—

(21494755) Public health laboratory ask at order entry panel

0.00

0.0

1.0

—

(3002434) Lupus erythematosus deoxynucleoproteins IgG Ab [Units/volume] in Serum by Immunoassay

0.00

0.0

1.3

—

(3020891) Body temperature

0.00

0.0

6.7

—

(3029338) Protein.monoclonal band 3 [Mass/volume] in Serum or Plasma by Electrophoresis

0.00

0.0

7.3

—

0.0

—

(3029379) Protein.monoclonal band 4 [Mass/volume] in Serum or Plasma by Electrophoresis

0.00

0.0

7.3

—

0.0

—

(3044254) Respiratory syncytial virus RNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.1

—

(3004383) Neutrophil cytoplasmic Ab.classic [Titer] in Serum by Immunofluorescence

0.00

0.0

1.2

—

(3027315) Oxygen [Partial pressure] in Blood

0.00

0.0

3.1

—

8.8

—

(3016407) Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay

0.00

0.0

4.5

—

3.7

—

(3000515) Antithrombin actual/normal in Platelet poor plasma by Chromogenic method

0.00

0.0

4.0

—

89.0

—

(3028286) Albumin [Mass/volume] in Serum or Plasma by Electrophoresis

0.00

0.0

7.3

—

34.4

—

(3005895) Myoglobin [Mass/volume] in Serum or Plasma

0.00

0.0

1.3

—

125.8

—

Mortality – FinRegistry

↥

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

Relationships between endpoints

↥

Index endpoint: CD2_INSITU_MELANOMA_EYELID – Melanoma in situ of eyelid, including canthus

GWS hits: -

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

≡ Risteys

FG R12 + FR

FinnGen R11 + FinRegistry

FinnGen R10 + FinRegistry

FinnGen R10

FinnGen R9

FinnGen R8

FinnGen R7

FinnGen R6

FinnGen R5

FinnGen R4

FinnGen R3

Melanoma in situ of eyelid, including canthus

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

All original rules

Similar endpoints

Case counts by codes

Case counts by code for Melanoma in situ of eyelid, including canthus (CD2_INSITU_MELANOMA_EYELID)

Summary Statistics

-FinRegistry-

-FinnGen-

Key figures

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

CodeWAS (R11)

LabWAS

Mortality – FinRegistry

Relationships between endpoints